舞蹈对帕金森病患者认知功能的重要性:通过元分析进行系统审查
Priscila Rodrigues Gil1, Jéssica Amaro Moratelli1, Danielly Yani Fausto1
1Postgraduate Program in Human Movement Sciences (PPGCMH), State University of Santa Catarina (UDESC), Brazil.
Journal of bodywork and movement therapies
|November 27, 2024
概括
舞蹈干预显示了改善帕金森病患者认知能力的潜力. 然而,研究方法的多样性和潜在的出版偏差需要仔细解释当前证据.
科学领域:
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
- 运动学 运动学
背景情况:
- 帕金森病 (PD) 是一种影响运动功能的神经退行性疾病,通常伴有认知能力下降.
- 在PD的认知障碍影响日常生活和生活质量.
- 探索舞蹈等非药物干预措施对于管理PD症状至关重要.
研究的目的:
- 系统地审查和综合有关舞蹈干预对帕金森病患者认知功能的有效性的证据.
- 评估现有研究的质量,并确定潜在的偏见.
主要方法:
- 进行了系统性审查和元分析,在PROSPERO (CRD42023474696) 中注册了该研究.
- 在过去10年内发表的研究中,在五个主要数据库 (PubMed Central®,Embase,Web of Science,ScienceDirect,Scopus Elsevier) 进行了电子搜索.
- 偏差风险使用Cochrane合作的RoB2和ROBINS-I工具进行了评估.
主要成果:
- 包括11项研究,评估偏差风险范围从低到中等.
- 在总体元分析中观察到显著的异质性 (I2 = 90%,p < 0.0001) 由于不同的舞蹈方式和认知评估工具.
- 然而,使用蒙特利尔认知评估 (MoCA) 分析的研究表明异质性较低 (I2 = 0%,p = 0.41),表明与标准化措施更一致的发现.
- 一个分散的漏斗图表表明了潜在的出版偏差.
结论:
- 舞蹈干预可以为帕金森病的认知功能提供好处.
- 研究设计和结果措施的异质性需要谨慎地解释研究结果.
- 需要进一步进行高质量的标准化研究,以确认PD管理中的舞蹈干预措施的有效性和最佳方案.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
10:28Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.1K
相关概念视频
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Social Facilitation
31.8K
Not all intergroup interactions lead to negative outcomes. Sometimes, being in a group situation can improve performance. Social facilitation occurs when an individual performs better when an audience is watching than when the individual performs the behavior alone. This typically occurs when people are performing a task for which they are skilled.
31.8K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
